Cefuroxime Axetil Tablets

This product is a second-generation cephalosporin antibiotic. After oral absorption through the gastrointestinal tract, it is rapidly hydrolyzed into cefuroxime under the action of esterase to exert its antibacterial effect. Its activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against the b-lactamase produced by Staphylococci and Gram-negative bacilli. Except for methicillin-resistant Staphylococci, Enterococci and Listeria, other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity of this product against Staphylococcus aureus is worse than that of cefazolin. 1-2 mg/L of this product can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. are sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, most Serratia are resistant, and Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

The main ingredient of this product is cefuroxime axetil. Molecular weight: C20H22N4O10S

This product is a film-coated tablet, which appears off-white after removing the coating.

No data yet

Oral administration. Adults generally take 0.5g a day; patients with lower respiratory tract infection: 1g a day; patients with simple lower urinary tract infection: 0.25g a day. Take it in 2 divided doses. The single-dose therapy dose for simple gonococcal urethritis is 1g. Children aged 5 to 12 years with acute pharyngitis or acute tonsillitis: 20mg/kg a day according to body weight, taken in 2 divided doses, not exceeding 0.5g a day; acute otitis media, impetigo: 30mg/kg a day according to body weight, taken in 2 divided doses, not exceeding 1g a day.

1. Common gastrointestinal reactions include diarrhea, nausea and vomiting. 2. Rare allergic reactions include rash and drug fever. 3. Occasionally, pseudomembranous colitis, eosinophilia, increased blood bilirubin, decreased hemoglobin, changes in renal function, positive Coombs test and transient increase in liver enzymes are seen.

1. It is contraindicated for patients who are allergic to this product and other cephalosporins, those with a history of anaphylactic shock or immediate reaction to penicillin, and those with gastrointestinal absorption disorders. 2. It is contraindicated for children under 5 years old.

Precautions for children: Children under 5 years old are prohibited from using this product. Cefuroxime axetil suspension is recommended. Precautions for pregnancy and lactation: 1. No evidence of harm to the fetus was found in animal experiments, but there is a lack of sufficient information in human studies. Therefore, pregnant women should use this product with caution only when there is a clear indication. 2. This product can be excreted through breast milk, so lactating women should use it with caution or stop breastfeeding. Precautions for the elderly: The blood elimination half-life (t1/2?) of elderly patients (average age 84 years old) can be extended to about 3.5 hours. Therefore, the dosage or medication interval should be adjusted according to the renal function under the guidance of a doctor.

1. Furosemide, ethacrynic acid, bumetanide and other strong diuretics, carmustine, streptozocin and other anti-tumor drugs and aminoglycoside antibiotics and other nephrotoxic drugs combined with this product may increase nephrotoxicity. 2. Clavulanic acid can enhance the antibacterial activity of this product against certain Gram-negative bacteria that are resistant to this product due to the production of β-lactamase. 3. This product combined with probenecid can increase the area under the drug-time curve (AUC value) of this product by about 50%. 4. This product combined with antacids can reduce the absorption of this product.

Light-proof and sealed.

Calculated as C16H16N4O8S 0.25g

24 months

Beijing Jingfeng Pharmaceutical Co., Ltd.

• Founded in:

  2002-03-06

• Address:

  Building 1, Building 9-10, Building 12-13, No. 21, Xiangrui Street, Daxing Biomedicine Industry Base, Zhongguancun Science Park, Daxing District, Beijing

• Tax NO.:

  91110000736469100Q

• Registered Funds:

  475.3425 million yuan

• Website:

  Log in to view

• Email:

  Log in to view